Abivax S.A. (ABVX)の価格はいくらですか

Abivax S.A. (ABVX)の価格は$120.16です

Abivax S.A. (ABVX)の時価総額は何ですか

Abivax S.A. (ABVX)の時価総額は$10.47Bです

Abivax S.A. (ABVX) の収益

Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.

年	収益	変化
提供された日付のデータは十分ではありません。

年

収益

変化

提供された日付のデータは十分ではありません。

企業	収益	収益の差	国
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Moderna, Inc. MRNA.US	$2.23B	-	US
CSL Limited CSL.AX	$15.74B	-	AU
Lonza Group AG LONN.SW	-	-	CH

企業

収益

収益の差

国

Vertex Pharmaceuticals Incorporated

VRTX.US

$12.62B

Argenx SE

ARGX.US

$6.02B

Moderna, Inc.

MRNA.US

$2.23B

CSL Limited

CSL.AX

$15.74B

Lonza Group AG

LONN.SW

Abivax S.A.

ABVX

カテゴリー